ClinicalTrials.gg
RecruitingNCT06190730RECOVERUpdated Nov 20, 2026

REmote Symptom COllection to improVE postopeRative Care

An interventional study of Voice-Assisted Remote Symptom Monitoring System (VARSMS) in Gastrointestinal Cancer, Gastrointestinal Tumor and Gastrointestinal Tumor Surgery, sponsored by Medstar Health Research Institute. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Medstar Health Research Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.
Updated Nov 20, 2026Enrollment updatedStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.

Planned enrollment
42nd of 245
266 · median 60
Started
2024
with 21 others
No phase
96 of 316
26 open now
Primary completion
2027-09
later than 59 of 113 live
Registered
263rd of 316
by date

Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 42nd largest by planned enrollment of the 245 interventional ones that give a count, is one of 22 that started in 2024, is one of 96 with no phase, reaches primary completion later than 59 of the 113 other live ones, and was the 263rd registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Gastrointestinal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

There are vulnerabilities in post-discharge care transition for patients after undergoing resection of gastrointestinal tumors. This study aims to investigate the possibility of utilizing Voice-Assisted Remote Symptom Monitoring System (VARSMS) to alleviate some of these challenges.

Read the detailed description

Randomized controlled trial comparing post-op patients randomized to using the VARSMS vs control.

03

Conditions studied

  • Gastrointestinal Cancer
  • Gastrointestinal Tumor
  • Gastrointestinal Tumor Surgery
  • Gastrointestinal Surgery

Keywords

  • speech system
  • large language model
  • ai
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years old. Ages of subjects >89 will simply be reported as >90.
  2. Scheduled for a GI surgery for management of a tumor in a participating hospital.
  3. Fluent in oral and written English.
  4. Has consistent and continued full access to an operational Wi-Fi for the duration of the study.

Exclusion criteria

Exclusion criteria

  1. Unable to provide .
  2. Not willing to commit to regular participation in the study to include daily use (40 days) of the study application.
  3. of less than 60 days.
  4. In the opinion of the investigator, participation in this study is .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
266 participants (estimated)

Study arms

  • No intervention
    Control

    Besides the consent process, subjects in this arm will have no other research-specific activities until after 40 days after the surgery for an exit interview.

  • Experimental
    Voice-Assisted Remote Symptom Monitoring System (VARSMS) group

    Subjects in this group will be issued the device, to be activated 1 day after discharge. The device will administer a set of questions daily.

    Other: Voice-Assisted Remote Symptom Monitoring System (VARSMS)

Interventions

  • OtherVoice-Assisted Remote Symptom Monitoring System (VARSMS)

    Utilizing an Alexa Skill activated via an Amazon Echo Dot device or Amazon Alexa mobile application, this system will administer two patient-reported outcomes measures to subjects. This will not be used as basis for diagnosis, nor for any clinical intervention.

    Also known as: Voice-Assisted Remote Symptom Monitoring System (VARSMS)- customization phase

06

What researchers measure

Primary outcomes

  1. Custom questionnaire based on NCI PRO CTCAE (National Cancer Institute- Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events)

    Daily symptom-based self-reported assessment on dyspnea, fever, melena, pain, wound healing, activities of daily living, sensorium, gastrointestinal motility, dysphagia, pitting edema, mood, and an option to mention symptoms not asked of. This is monitored by the research team, and any concerning finding, at the discretion of the site's physician, will be relayed to the subject's treating physician. Treating physician has final decision on whether to address referral by adjustment of management.

    Time frame: 40 days

Secondary outcomes

  1. SASSI (Subjective Assessment of Speech System Interfaces)

    After interacting with the speech system for 40 days from the day after discharge, this questionnaire assesses the patient on their experience, having them rate the system based on system response accuracy, likeability, cognitive demand, annoyance, habitability, and speed.

    Time frame: 40 days

07

Study locations

3 of 3 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Sep 2027, 38 months after the start.

Of 154 non-industry interventional studies with no phase under Gastrointestinal Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 38 months is close to that.

Counting every sponsor, half of 164 studies reached it within 36 months; a quarter within 17 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 5, 2024
StartActual
Jul 23, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • MedStar Health · Washington D.C., United States
Nov 20, 2026
Enrollment
281→266
Nov 20, 2026
Contact
Study contact changed: c•••@medstar.net · •••8218→p•••@medstar.net · •••2909. See the current contact
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    1 site added
    Show site
    • MedStar Health · Washington D.C., United States
    Enrollment 281→266
    Contact Study contact changed: c•••@medstar.net · •••8218→p•••@medstar.net · •••2909. See the current contact
    + 5 other changes: verification date, oversight details, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06190730
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Jul 23, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Nawar Shara, PhD
Contact
nawar.shara@medstar.net
301-502-0339
Prabhjeet Singh, MSPH
Contact
prabhjeet.singh@medstar.net
732-796-2909

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion